Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual
- PMID: 30522048
- PMCID: PMC6354576
- DOI: 10.1016/j.drugalcdep.2018.10.035
Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual
Abstract
Background: Criminal justice involved (CJS) populations with opioid use disorder (OUD) have high rates of relapse, future arrests, and death upon release. While medication for OUD (MOUD) reduces opioid relapse, concerns regarding diversion and stigma limit treatment in CJS populations. Extended release naltrexone (XR-NTX), as an opioid antagonist, may be more acceptable to CJS administrators. However, the impact of XR-NTX on criminal recidivism remains unknown.
Methods: Arrest data from a published randomized trial comparing XR-NTX to treatment as usual (TAU) was captured by self-report and official state arrest records. Comparisons of future arrests, time to first arrest and total number of arrests were performed using chi square tests and multivariable generalized regression models. Secondary outcomes explored differences in arrests by type and severity of crime, use of opioid and other drugs, and study phase.
Results: Of 308 participants randomized, 300 had arrest data. The incidence of arrests did not differ between XR-NTX (47.6%) and TAU (42.5%) participants. (ChiSq p = 0.37). Additionally, there was no significant difference in time to first arrest (adjusted HR 1.35, CI 0.96-1.89) and number of arrests per participant (adjusted IR 1.33, CI 0.78-2.27). Controlling for gender, age, previous criminal activity, and use of non-opioid drugs, logistic regression demonstrated no significant difference in incidence of arrests between groups (adjusted OR 1.38, 95% CI 0.85-2.22).
Conclusions: We detected no significant difference in arrests between CJS participants with OUD randomized to XR-NTX or TAU. Despite its efficacy in reducing opioid use, XR-NTX alone may be insufficient to reduce criminal recidivism.
Keywords: Criminal recidivism; Extended release naltrexone; Opioid use disorder.
Copyright © 2018. Published by Elsevier B.V.
Conflict of interest statement
Conflicts of interest: In-kind medication was provided for this study by Alkermes in the original randomized trial.
Figures

Similar articles
-
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.Contemp Clin Trials. 2015 Mar;41:110-7. doi: 10.1016/j.cct.2015.01.005. Epub 2015 Jan 17. Contemp Clin Trials. 2015. PMID: 25602580 Free PMC article. Clinical Trial.
-
Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.J Subst Abuse Treat. 2018 Feb;85:66-69. doi: 10.1016/j.jsat.2017.05.009. Epub 2017 May 12. J Subst Abuse Treat. 2018. PMID: 28576389
-
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.J Subst Abuse Treat. 2020 Oct;117:108076. doi: 10.1016/j.jsat.2020.108076. Epub 2020 Jul 6. J Subst Abuse Treat. 2020. PMID: 32811623 Free PMC article. Clinical Trial.
-
Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24. Addiction. 2018. PMID: 29396985 Free PMC article.
-
Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.Addiction. 2020 Aug;115(8):1413-1425. doi: 10.1111/add.14946. Epub 2020 Jan 17. Addiction. 2020. PMID: 31863669
Cited by
-
Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell Syst Rev. 2022 Jan 7;18(1):e1215. doi: 10.1002/cl2.1215. eCollection 2022 Mar. Campbell Syst Rev. 2022. PMID: 36913194 Free PMC article.
-
Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.Drug Alcohol Depend. 2020 Mar 1;208:107837. doi: 10.1016/j.drugalcdep.2020.107837. Epub 2020 Jan 9. Drug Alcohol Depend. 2020. PMID: 31951906 Free PMC article.
-
Interventions for female drug-using offenders.Cochrane Database Syst Rev. 2019 Dec 13;12(12):CD010910. doi: 10.1002/14651858.CD010910.pub3. Cochrane Database Syst Rev. 2019. PMID: 31834635 Free PMC article.
-
Interventions for drug-using offenders with co-occurring mental health problems.Cochrane Database Syst Rev. 2019 Oct 7;10(10):CD010901. doi: 10.1002/14651858.CD010901.pub3. Cochrane Database Syst Rev. 2019. PMID: 31588993 Free PMC article. Review.
References
-
- Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, OBrien CP, 2006. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Arch Gen Psychiatry, 63(2), 210–218. doi: 10.1001/archpsyc.63.2.210 - DOI - PMC - PubMed
-
- Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, and Wodak AD, 2003. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend, 72(1), 59–65. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical